



What You Need to Know about Zapnex and the risk of Agranulocytosis

What You Need to Know about Zapnex and agranulocytosis:


Zapnex is a prescription medicine to treat people with schizophrenia who have not responded to other medicines. Zapnex may also reduce the risk of suicidal behavior.

What is the most serious risk information about Zapnex treatment?

Agranulocytosis is a blood disorder that occurs when a certain type of white blood cells called neutrophils are not made or not enough of them are made.

Before you can start Zapnex and during treatment, you must have regular blood tests to measure number of neutrophils you have in your blood. This test is called absolute neutrophil count (ANC). If the number of neutrophils, or ANC, is too low, you may have to stop Zapnex. Your doctor will decide if or when it is safe to restart Zapnex.

You might not have any symptoms at all. Getting your blood tested to measure the number of neutrophils is the only way to check for agranulocytosis. This helps your doctor know if you are more likely to get an infection.



- ## What You Need to Know about Zapnex and agranulocytosis:

Three important things you can do:

- ### What are the blood testing requirements for Zapnex?

- Your doctor will give you an order to have blood tests done
- You will need to get your blood tested on the following schedule or as directed by your doctor:
 - Weekly blood tests for the first 6 months you are taking Zapnex
 - Every 2 weeks for the next 6 months If your ANC stays normal
 - Every 4 weeks after the first year if your ANC stays normal

- If your ANC is too low, your doctor will schedule blood tests more frequently

- Remember: you must get your blood tested before you can receive Zapnex from your Pharmacy!

Please refer to Patient Information Leaflet for more information.

- **The National Pharmacovigilance Center (NPC)**
 - ~~Fax:~~
+966 11 205 7662
 - ~~Toll-free phone:~~
8002490000
 - **SFDA Call Center:**
19999
 - **E-mail:** **npc.drug@sfd.gov.sa**
 - **Website:** **https://ade.sfd.gov.sa/**

You should also report any side effects to Aurobindo Pharma Saudi Arabia Limited, Jeddah, Pharmacovigilance department on +966 (0) 12 6688856 Ext. 107 or pv.papsal@aurobindo.com

This patients guide was last approved in 10/2020, version number is 00